Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-2/3
2006-002704-34Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hepatitis C virus infection comparing Albinterferon alfa-2b plus ribavirin with Pegasys plus ribavirin (2 arms). Primary endpoint: Sustained virologic response. Started Jan 2007; status: completed.
02
Drugs
albinterferon alfa-2bpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-002704-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002704-34.